NORWOOD, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024. Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFormat: Presentation and one-on-one investor meetingsP ...

Key PointsCorbus Pharmaceuticals has surged over 300% year-to-date after releasing promising data on January 26 from its Phase 1 trial on CRB-701.Oppenheimer's target raise to $51, alongside a significant insider purchase, signals optimism for Corbus Pharmaceuticals.Recent insider purchasing of over $9 million indicates strong confidence in Corbus Pharmaceuticals' future.5 stocks we like better than Corbus PharmaceuticalsShares of Corbus Pharmaceuticals NASDAQ: CRBP have already experienced a meteoric rise ...

NORWOOD, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today announced the closing of its public offering of 4,973,750 shares of its common stock, including 648,750 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares. All of the common stock was sold at a public offering price of $19.00 per share for a total public offering ...

NORWOOD, Mass., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a precision oncology company with a diversified portfolio, today announced that it plans to offer and sell shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock in an underwritten registered public offering. All of the securities in the offering are to be sold by Corbus. The offering is subject to ...

Andy Roberts/OJO Images via Getty Images Topline Summary Corbus Pharmaceuticals (NASDAQ:CRBP) is a microcap biotech company focused on the development of novel therapies for the treatment of cancer. They've recently experienced a meteoric surge out of the depths on the back of a positive clinical readout, but it remains very early days for the company's overall pipeline, and cash is not sufficient to keep the ball rolling without some significant financing needed. It's best to hold off on this one for n ...

The stock of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) closed up nearly 250% last week. The gains happened after favourable pharmaceutical news that saw the stock climb above $29. CRBP was previously trading at a meagre valuation below $7. Despite the stock trading almost 25% lower in premarket on Monday, the developments are worth attention. Corbus Pharmaceuticals is a precision oncology company seeking to help people defeat serious illnesses. The company targets very rare and serious diseases us ...

Shares of little-known Corbus Pharmaceuticals (NASDAQ:CRBP) are absolutely skyrocketing today. At the time of writing, CRBP stock is up more than 300%, as investors price in a key announcement from the company. Earlier today, Corbus announced that its next-generation antibody drug (CRB-701) showed strong safety and efficacy in a first-in-human study on its effects on cervical cancer tumors. This drug conjugate is one of three key drugs that are currently in clinical trial phases but has clearly moved up the ...

Q3W schedule of CRB-701 (SYS6002) demonstrates a 43% ORR and 71% DCR at predicted therapeutically relevant dosesAll assessable nectin-4 positive study participants with mUC and cervical cancer treated at or above this dose demonstrated some level of disease controlNo dose limiting toxicities (DLTs) have been observed to-date up to 3.6 mg/kg (cohort 6) with further escalation at 4.5 mg/kg ongoingNo cases of peripheral neuropathy or skin rash have been observed to dateCohort 6 is the first cohort selected for ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or For the transition period from________ to_________. Corbus Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) (Former Name, Former Address and Former Fiscal Year if Changed Since Last Report): N/A Title of Each Class Exchange on Which Registered TradingSymbolNameofEach Large accelerated filer ☐ Accelerated filer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to_________. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 500 River Ridge Drive Norwood, MA ...